- 0%
- 0%
- 0%
- 0%
- 0%
Report this review.
ARA-290 reduces damaging inflammation and helps protect cells and tissues after injury by activating the body's own survival signals.
Biological context and relevance
ARA-290 is a short peptide derived from the helix B region of erythropoietin and is studied as a selective activator of a non‑erythropoietic, tissue‑protective signaling complex. In experimental systems it is used to probe pathways of inflammation resolution, cell survival, and repair across peripheral tissues and the central nervous system. The molecule is of interest in translational research on neuropathic pain, inflammatory small‑fiber neuropathies and ischemic injury.
Mechanism of action
ARA-290 engages a heteromeric receptor complex described as the innate repair receptor to trigger downstream cytoprotective cascades. Binding leads to modulation of intracellular kinases and transcriptional regulators that reduce pro‑inflammatory cytokine release, limit apoptotic signaling and promote metabolic resilience in stressed cells. These actions have been documented in peripheral immune cells and resident glia, indicating both peripheral and central components to its tissue-protective activity. The peptide does not stimulate hematopoiesis at concentrations used for tissue protection, reflecting its selective receptor engagement. non-erythropoietic
Selected clinical and preclinical data
| Study | Population / model | N | Duration | Key observed outcomes |
|---|---|---|---|---|
| Phase 2 sarcoidosis-associated small fiber neuropathy | Adults with sarcoidosis-associated neuropathic symptoms | 22 | 28 days | Reported reductions in neuropathic symptom scores and improvements in small-fiber function; data are preliminary and from controlled trial settings |
| Rodent ischemia–reperfusion models (preclinical) | Rat/mouse cardiac and renal ischemia models | 8–12 per group | Acute (hours–days) | Reduced markers of tissue injury and inflammatory cytokines versus control groups |
Research use and experimental considerations
ARA-290 is employed in studies of neuropathy, ischemia–reperfusion injury, and immune modulation; available data derive from controlled laboratory, preclinical and early clinical environments. Reported pharmacokinetic descriptions indicate a short biological half‑life consistent with rapid receptor engagement and transient signaling, which should inform dosing schedules and sampling in experimental designs. neuropathic pain
Chemical formula: C53H82N14O14
Sources: ARA-290 Wikipedia article, Peer-reviewed clinical report on ARA-290, Preclinical studies of ARA-290
Note: This content is intended for educational and research purposes only.
Similar
